HELP YOUR
PATIENTS ACCESS HA

+ Trusted

35 million doses administered worldwide1†
TriVisc efficacy established by equivalence to Visco-3 ®2
Visco-3 determined to be non-inferior to Euflexxa®3
Supported by published clinical data
TriVisc exhibited improvement in WOMAC and VAS scores compared to baseline4,5,6

+ Pure₁

Highly purified HA produced by bacterial biofermentation technology
Removes the risk of avian allergies and sensitivities
Consistent viscolastic properties, safe for repeat injection cycles
Fully automated manufacturing process minimizes the risk of contamination and human error